EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020

Elisabeth Bakker iD, Viktoriia Starokozhko, Jet W M Kraaijvanger, Hiddo J L Heerspink, Peter G M Mol

Clinical and Translational Science · 2023

DOI: 10.1111/cts.13641 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2023. Verfasst von Elisabeth Bakker und 4 weiteren Autor:innen. Beteiligte Einrichtung: University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Precision Medicine, Decision Making. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Innovative Medicines Initiative, Horizon Europe Research and Innovation Actions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biomarkers can guide precision medicine in clinical trials and practice. They can increase clinical trials' efficiency through selection of study populations more likely to benefit from treatment, thus increasing statistical power and reducing sample size requirements or study duration. We performed a narrative synthesis to explore biomarker utilization for patient selection to guide precision medicine trials in marketing authorization dossiers of centrally approved medicines in Europe between 2018 and 2020 and analyzed in‐depth those that eventually included biomarkers in the medicines' indications. From 119 eligible products, 26 included a biomarker in the indication, of which most were oncology products ( n = 15). Included biomarkers were often known from literature or from previously approved products in the European Union or the United States. Additionally, 52 dossiers mentioned one or more biomarkers for patient selection in their clinical efficacy and safety information. Although these were not always included in the medicines' indication, they were often implicitly embedded in condition definitions adopted from clinical guidelines or practice. In 15 out of the 26 medicines with a biomarker‐guided indication, only biomarker‐positive populations were included in the main clinical studies supporting the marketing authorization. These studies were mostly randomized controlled trials or single‐arm trials; only two products were studied for multiple indications in an innovative basket trial. Definitions of biomarkers could be subject of debate and needed adaptation after post hoc analyses requested by the assessment committee in four cases, stressing the importance of thorough justification of these definitions to include the right population for an optimal benefit–risk balance, enabling precise medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineDecision MakingHumansUnited StatesPatient SelectionEuropeBiomarkersDrug Approval

Substanzen

Biomarkers

Autor:innen und Institutionen

  • University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
  • Dutch Medicines Evaluation Board, CBG-MEB, Utrecht, The Netherlands.
  • VU University Amsterdam, Amsterdam, The Netherlands.

ORCID-Profile: Elisabeth Bakker

Förderung

  • Innovative Medicines Initiative
  • Horizon Europe Research and Innovation Actions

Zitieren

APA

Bakker, E., Starokozhko, V., Kraaijvanger, J. W. M., Heerspink, H. J. L., & Mol, P. G. M. (2023). Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020. Clinical and Translational Science. https://doi.org/10.1111/cts.13641

Vancouver

Bakker E, Starokozhko V, Kraaijvanger JWM, Heerspink HJL, Mol PGM. Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020. Clinical and Translational Science. 2023. doi:10.1111/cts.13641

BibTeX
@article{Bakker2023,
  author = {Bakker, Elisabeth and Starokozhko, Viktoriia and Kraaijvanger, Jet W M and Heerspink, Hiddo J L and Mol, Peter G M},
  title = {Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020},
  journal = {Clinical and Translational Science},
  year = {2023},
  doi = {10.1111/cts.13641}
}
Kostenlos starten →